EIT Pharma Showcases Promising Results in Hepatitis Treatment at The Liver Meeting 2026
EIT Pharma Showcases Promising Results in Hepatitis Treatment at The Liver Meeting 2026
EIT Pharma, Inc., a leading biotechnology firm dedicated to addressing infectious diseases, is set to present groundbreaking data at The Liver Meeting®, an esteemed annual gathering organized by the American Association for the Study of Liver Diseases (AASLD). Scheduled for November 5-9, 2026, in Denver, Colorado, this conference will bring together influential researchers, healthcare professionals, and industry stakeholders who are at the forefront of hepatology.
During the event, EIT Pharma will share extensive findings from the phase 3 D-LIVR trial. This trial investigated the efficacy of lonafarnib, the only investigational oral therapy currently in late-stage development for patients suffering from Chronic Hepatitis D (CHD). What makes their findings particularly significant is the evidence demonstrating treatment benefits continuing even after the cessation of therapy, thereby supporting the potential use of lonafarnib as a finite treatment option for CHD.
EIT Pharma’s Presentation Details
Session: Hepatitis - Other Infections
Title: Durable and newly emergent treatment response during a 24-week follow-up in a finite lonafarnib treatment regimen extended analyses from the phase 3 D-LIVR trial
Presenter: Professor Tarik Asselah MD, PhD
- - Position: Professor of Hepatology at Université Paris Cité and a hepatologist at Hôpital Beaujon, Assistance Publique–Hôpitaux de Paris
Date: Sunday, November 8, 2026
Time: 3:00 P.M. MST
The context is critical as Chronic Hepatitis D is a severe liver disease that often complicates existing hepatitis B infections. The recent acceptance of EIT Pharma's New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) marks a pivotal moment in seeking approval for lonafarnib as a viable treatment option. Such developments hold promise for addressing unmet medical needs in patients suffering from hepatitis-related complications.
Understanding Lonafarnib
Lonafarnib represents a novel approach to combating hepatitis D. By specifically targeting a crucial phase in the hepatitis D virus life cycle, this investigational therapy aims to effectively reduce viral load and improve patient outcomes. Despite still undergoing evaluation and awaiting regulatory approval, the potential for lonafarnib to revolutionize treatment protocols for CHD patients cannot be overlooked. As of now, no other oral therapeutic candidates are available in the advanced stages of clinical development for this condition.
About EIT Pharma, Inc.
EIT Pharma's portfolio is driven by a mission to enhance patient care through rigorous scientific inquiry and innovation. With a keen focus on infectious diseases that have long been neglected, EIT Pharma is passionately committed to translating scientific advancements into real-world solutions. Their strategies integrate patient-centered approaches and scientific rigor to provide meaningful improvements in health outcomes.
As EIT Pharma prepares to present at The Liver Meeting 2026, the scientific community eagerly anticipates their findings and the impact they will have on future treatment landscapes for liver diseases. The continued research efforts underscore the important relationship between medical innovation, regulatory frameworks, and patient outreach in the fight against complex infectious diseases.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.